Identifying protein targets for drugs establishes an indispensable knowledge foundation for drug repurposing and drug development. Though expensive and time-consuming, vitro trials are widely employed to discover drug targets, and the existing relevant computational algorithms still cannot satisfy the demand for real application in drug R&D with regards to the prediction accuracy and performance efficiency, which are urgently needed to be improved. To this end, we propose here the PPAEDTI model, which uses the graph personalized propagation technique to predict drug-target interactions from the known interaction network. To evaluate the prediction performance, six benchmark datasets were used for testing with some state-of-the-art methods compared. As a result, using the 5-fold cross-validation, the proposed PPAEDTI model achieves average AUCs>90% on 5 collected datasets. We also manually checked the top-20 prediction list for 2 proteins (hsa:775 and hsa:779) and a kind of drug (D00618), and successfully confirmed 18, 17, and 20 items from the public datasets, respectively. The experimental results indicate that, given known drug-target interactions, the PPAEDTI model can provide accurate predictions for the new ones, which is anticipated to serve as a useful tool for pharmacology research. Using the proposed model that was trained with the collected datasets, we have built a computational platform that is accessible at http://120.77.11.78/PPAEDTI/ and corresponding codes and datasets are also released.

Recently, the role of competing endogenous RNAs in regulating gene expression through the interaction of microRNAs has been closely associated with the expression of circular RNAs (circRNAs) in various biological processes such as reproduction and apoptosis. While the number of confirmed circRNA–miRNA interactions (CMIs) continues to increase, the conventional in vitro approaches for discovery are expensive, labor intensive, and time consuming. Therefore, there is an urgent need for effective prediction of potential CMIs through appropriate data modeling and prediction based on known information. In this study, we proposed a novel model, called DeepCMI, that utilizes multi-source information on circRNA/miRNA to predict potential CMIs. Comprehensive evaluations on the CMI-9905 and CMI-9589 datasets demonstrated that DeepCMI successfully infers potential CMIs. Specifically, DeepCMI achieved AUC values of 90.54% and 94.8% on the CMI-9905 and CMI-9589 datasets, respectively. These results suggest that DeepCMI is an effective model for predicting potential CMIs and has the potential to significantly reduce the need for downstream in vitro studies. To facilitate the use of our trained model and data, we have constructed a computational platform, which is available at http://120.77.11.78/DeepCMI/. The source code and datasets used in this work are available at https://github.com/LiYuechao1998/DeepCMI.

Computational prediction of miRNAs, diseases, and genes associated with circRNAs has important implications for circRNA research, as well as provides a reference for wet experiments to save costs and time. In this study, SGCNCMI, a computational model combining multimodal information and graph convolutional neural networks, combines node similarity to form node information and then predicts associated nodes using GCN with a distributive contribution mechanism. The model can be used not only to predict the molecular level of circRNA–miRNA interactions but also to predict circRNA–cancer and circRNA–gene associations. The AUCs of circRNA—miRNA, circRNA–disease, and circRNA–gene associations in the five-fold cross-validation experiment of SGCNCMI is 89.42%, 84.18%, and 82.44%, respectively. SGCNCMI is one of the few models in this field and achieved the best results. In addition, in our case study, six of the top ten relationship pairs with the highest prediction scores were verified in PubMed.

Abnormal microRNA (miRNA) functions play significant roles in various pathological processes. Thus, predicting drug–miRNA associations (DMA) may hold great promise for identifying the potential targets of drugs. However, discovering the associations between drugs and miRNAs through wet experiments is time-consuming and laborious. Therefore, it is significant to develop computational prediction methods to improve the efficiency of identifying DMA on a large scale. In this paper, a multiple features integration model (MFIDMA) is proposed to predict drug–miRNA association. Specifically, we first formulated known DMA as a bipartite graph and utilized structural deep network embedding (SDNE) to learn the topological features from the graph. Second, the Word2vec algorithm was utilized to construct the attribute features of the miRNAs and drugs. Third, two kinds of features were entered into the convolution neural network (CNN) and deep neural network (DNN) to integrate features and predict potential target miRNAs for the drugs. To evaluate the MFIDMA model, it was implemented on three different datasets under a five-fold cross-validation and achieved average AUCs of 0.9407, 0.9444 and 0.8919. In addition, the MFIDMA model showed reliable results in the case studies of Verapamil and hsa-let-7c-5p, confirming that the proposed model can also predict DMA in real-world situations. The model was effective in analyzing the neighbors and topological features of the drug–miRNA network by SDNE. The experimental results indicated that the MFIDMA is an accurate and robust model for predicting potential DMA, which is significant for miRNA therapeutics research and drug discovery.

The tumor microenvironment is a dynamic eco system where cellular interactions drive cancer progression. However, inferring cell-cell communication from non-spatial scRNA-seq data remains challenging due to incomplete li gand-receptor databases and noisy cell type annotations. H ere, we propose scGraphDap, a graph neural network frame work that integrates functional state pseudo-labels and graph structure learning to improve both cell type annotation an d CCC inference. By leveraging pathway activity scores (e. g., angiogenesis, apoptosis) as pseudo-labels, scGraphDap optimizes cell-cell graphs to capture functional proximity be yond geometric similarity. Furthermore, a graph domain adaptation module aligns cell embeddings across patients, enhancing cross-individual generalization. Evaluated on 38,667 cells from 15 patients across three cancers, scGraphDap ac hieved an average accuracy of 82.82%. Statistical validation confirmed its ability to recover disease-specific gene interactions (e.g., STAT3-CD274 in breast invasive carcinoma) without prior knowledge. The source code and data used in this paper can be found in https://github.com/LiYuechao1998/sc GraphDap. Our work provides a unified framework for TME analysis, offering insights into therapeutic target discovery.